Plain-English translation of NCT05428007 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether , a medication that blocks a protein called interleukin-6 receptor, works better when combined with three other immunotherapy medications (ipilimumab, nivolumab, and relatlimab) to treat advanced melanoma. The trial has two stages: the first stage gives all four medications to about 33 people, and the second stage randomly assigns 72 people to receive either the three standard medications with or without the new medication. The goal is to see if adding this medication improves how well the treatment works and whether it is safe.
Advanced melanoma is a serious type of skin cancer that can be life-threatening. While some immunotherapy treatments exist, doctors want to find better ways to help more patients. This medication is being tested because it may help the body's immune system fight cancer cells even more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive injections and infusions of the study medications over a 24-week initial treatment period, followed by continued treatment for up to two years. In the first stage, you will get all four medications; in the second stage, you will randomly receive either three or four medications. You will need to visit the clinic every 2 to 4 weeks for injections and infusions, have regular blood tests and imaging scans (CT and MRI), and sometimes have small tissue samples taken from your tumors to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States